What Tremfya treats
Tremfya (guselkumab) is a biologic medication used to treat moderate to severe plaque psoriasis and active psoriatic arthritis in adults. It works by targeting interleukin-23 (IL-23), a protein involved in the inflammatory process that contributes to the development of psoriasis and psoriatic arthritis. By inhibiting IL-23, Tremfya helps to reduce inflammation and improve symptoms in patients with these chronic conditions.
Benefits of Tremfya
Patients using Tremfya often experience significant benefits, including clearer skin, reduced symptoms of psoriatic arthritis, and improved physical function. The medication helps to reduce inflammation, providing relief from the discomfort of plaque psoriasis and psoriatic arthritis. The convenient dosing schedule—every eight weeks after the initial doses—makes Tremfya a practical option for long-term management of these conditions.
Possible Side Effects of Tremfya
While Tremfya is generally well-tolerated, some patients may experience side effects, including upper respiratory infections, headache, and injection site reactions such as redness or swelling. Serious side effects are rare but can include increased risk of infections and allergic reactions. It is important to monitor for any adverse effects and report them to your healthcare provider.
How infusion works at Prime
Tremfya is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Tremfya, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Tremfya Work?
Tremfya works by binding to and inhibiting IL-23, a cytokine that plays a key role in the inflammatory pathways that cause plaque psoriasis and psoriatic arthritis. By blocking IL-23, Tremfya reduces the activation of immune cells that trigger skin and joint inflammation. This leads to clearer skin in patients with psoriasis and improved joint function in those with psoriatic arthritis. Tremfya is administered through subcutaneous injections, typically given every eight weeks after initial doses.
Who is Tremfya For?
Tremfya is suitable for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for those with active psoriatic arthritis. It is recommended for patients who need targeted therapy to manage inflammation and improve their quality of life. Tremfya is used when other treatments may not have provided adequate control of the disease.